CN Patent

CN117222739A — 朊病毒蛋白(prnp)irna组合物和其使用方法

Assigned to Alnylam Pharmaceuticals Inc · Expires 2023-12-12 · 2y expired

What this patent protects

本公开涉及靶向朊病毒蛋白(PRNP)基因的双链核糖核酸(dsRNAi)药剂和组合物，以及抑制PRNP基因的表达的方法，以及使用此类dsRNAi药剂和组合物治疗患有PRNP相关疾病或病症，例如朊病毒病的受试者的方法。

USPTO Abstract

本公开涉及靶向朊病毒蛋白(PRNP)基因的双链核糖核酸(dsRNAi)药剂和组合物，以及抑制PRNP基因的表达的方法，以及使用此类dsRNAi药剂和组合物治疗患有PRNP相关疾病或病症，例如朊病毒病的受试者的方法。

Drugs covered by this patent

Patent Metadata

Patent number
CN117222739A
Jurisdiction
CN
Classification
—
Expires
2023-12-12
Drug substance claim
No
Drug product claim
No
Assignee
Alnylam Pharmaceuticals Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.